| Name | Title | Contact Details |
|---|
Located in Twinsburg Ohio, Edgepark is the nation's leading provider of medical supplies including ostomy, wound care, incontinence and diabetic supplies. Edgepark Surgical is a family-owned business driven by culture and values. Four fully-stocked
Flowcardia is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
KDA Triglav Systems Ltd is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Headquartered in Largo, Florida, BioDerm is a leading provider of disposable medical devices and wound care supplies to patients with chronic conditions. BioDerm manufactures proprietary hydrocolloid products for urinary management, securement, infection control and skin protection, challenging accepted inferior standards of care by creating products that reduce infection rates, add comfort and reliability, and vastly improve quality of life. BioDerm`s flagship products for male urinary incontinence are Men`s Liberty for the home setting and Men`s Liberty Acute for in-patient settings. Other products include CathGrip for securement and BioPlus and FreeDerm for skin protection.
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.